These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 22071063

  • 1. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ.
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [Abstract] [Full Text] [Related]

  • 2. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S, Wallace L, Alexander J, Istwan N.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [Abstract] [Full Text] [Related]

  • 3. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
    González-Quintero VH, de la Torre L, Rhea DJ, Tudela CM, Vazquez-Vera E, Desch C, Istwan NB.
    Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
    [Abstract] [Full Text] [Related]

  • 4. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 5. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G.
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [Abstract] [Full Text] [Related]

  • 6. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 7. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 8. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 9. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B, Poole-Yaeger A, Istwan N, Stanziano G, Rhea D, Mason M.
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [Abstract] [Full Text] [Related]

  • 10. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ.
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [Abstract] [Full Text] [Related]

  • 11. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Feghali M, Boyle A, Istwan N, Rhea D, Driggers RW.
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [Abstract] [Full Text] [Related]

  • 12. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [Abstract] [Full Text] [Related]

  • 13. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 14. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA, Garite TJ, Maurel K, Abril D, Das A, Clewell W, Heyborne K, How H, Huang W, Lewis D, Lu G, Miller H, Nageotte M, Porreco R, Sheikh A, Tran L, Obstetrix Collaborative Research Network.
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [Abstract] [Full Text] [Related]

  • 15. Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
    Cohen G, Shavit M, Miller N, Moran R, Yagur Y, Weitzner O, Ovadia M, Schreiber H, Shechter-Maor G, Biron-Shental T.
    PLoS One; 2022 Sep; 17(5):e0268397. PubMed ID: 35551554
    [Abstract] [Full Text] [Related]

  • 16. Does the clinical presentation of a prior preterm birth predict risk in a subsequent pregnancy?
    Drassinower D, Običan SG, Siddiq Z, Heller D, Gyamfi-Bannerman C, Friedman AM.
    Am J Obstet Gynecol; 2015 Nov; 213(5):686.e1-7. PubMed ID: 26215326
    [Abstract] [Full Text] [Related]

  • 17. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 18. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
    Romero J, Rebarber A, Saltzman DH, Schwartz R, Peress D, Fox NS.
    Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
    [Abstract] [Full Text] [Related]

  • 19. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

  • 20. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO, Stamilio DM, Macones GA, Polsky D.
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.